Bolt Biotherapeutics, Inc. BOLT
Bolt Biotherapeutics, Inc. (Nasdaq: BOLT) is an oncology drug developer. Its lead program, BDC-4182, is in Phase 1 for claudin 18.2-positive gastric/gastroesophageal junction cancer.
Upcoming catalysts
No catalyst is dated to the next 30 days or to an FDA action date.
Pipeline
| Program | Indication | Modality | Stage |
|---|---|---|---|
| BDC-4182 (claudin 18.2 Boltbody ISAC) | gastric/GEJ cancer | antibody | Phase 1 |
| BDC-3042 (dectin-2 agonist antibody) | solid tumors | antibody | Phase 1 |
| CEA ISAC | CEA-expressing solid tumors | antibody | Pre-clinical |
| PD-L1 ISAC | PD-L1-expressing tumors | antibody | Pre-clinical |
Recent results and decisions
- Oct 1, 2026positive BDC-4182 Phase 1 dose-escalation study showed disease control rate of 53% in patients treated every 2 weeks with no dose-limiting toxicities observed.
BDC-4182 was tolerated with mostly Grade 1/2 immune-related adverse events. No dose-limiting toxicities were observed, and a maximum tolerated dose was not reached.
Filing
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
Other phase 1 oncology companies
- Erasca, Inc. ERAS
- Parabilis Medicines, Inc. PBLS
- Xencor Inc XNCR
- Schrodinger, Inc. SDGR
- Vir Biotechnology, Inc. VIR
- Zymeworks Inc. ZYME
- Janux Therapeutics, Inc. JANX
- Aktis Oncology, Inc. AKTS
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.